Skip to content

Research at St Andrews

A Phase IB open-label, dose-escalation study of NUC 1031 in combination with carboplatin for recurrent ovarian cancer

Research output: Contribution to journalArticlepeer-review

Open Access Status

  • Embargoed (until 19/03/22)


F Kazmi, S Nicum, R Roux, L Spiers, C Gnanaranjan, A Sukumaran, H Gabra, Essam Ghazaly Kerwash, N McCracken, David James Harrison, S P Blagden

School/Research organisations


Purpose: NUC-1031 is a first-in-class ProTide modification of gemcitabine. In PRO-002, NUC‑1031 was combined with carboplatin in recurrent ovarian cancer (OC). Experimental Design: NUC-1031 was administered on days 1 & 8 with carboplatin on day 1 every 3 weeks for up to 6 cycles. Four dose cohorts of NUC-1031 (500, 625 and 750 mg/m2) with carboplatin (AUC4 or 5) were investigated. Primary endpoint was RP2CD. Secondary endpoints included safety, investigator-assessed objective response rate (ORR), clinical benefit rate (CBR), progression-free survival (PFS) and pharmacokinetics (PK). Results: 25 women with recurrent OC, a mean of 3.8 prior lines of chemotherapy and a median platinum-free interval (PFI) of 5 months (range: 7 - 451 days) were enrolled, 15/25 (60%) platinum-resistant; 9 (36%) partially platinum-sensitive and 1 (4%) platinum-sensitive. Of the 23 response-evaluable: there was 1 confirmed complete response (CR, 4%), 5 partial responses (PR, 17%) and 8 (35%) stable disease (SD). The ORR was 26% and CBR was 74% across all doses and 100% in the RP2CD cohort. Median PFS was 27.1 weeks. NUC-1031 was stable in the plasma and rapidly generated high intracellular dFdCTP levels that were unaffected by carboplatin. Conclusions: NUC-1031 combined with carboplatin is well tolerated in recurrent OC. Highest efficacy was observed at the RP2CD of 500 mg/m2 NUC-1031 on days 1 & 8 with AUC5 carboplatin day 1, every 3 weeks for 6 cycles. The ability to deliver carboplatin at AUC5 and the efficacy of this schedule even in patients with platinum-resistant disease makes this an attractive therapeutic combination.


Original languageEnglish
JournalClinical Cancer Research
Early online date19 Mar 2021
Publication statusE-pub ahead of print - 19 Mar 2021

    Research areas

  • Acelarin, NUC-1031, Platinum-resistance, Recurrent ovarian cancer

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Assessment of immunological features in muscle-invasive bladder cancer prognosis using ensemble learning

    Gavriel, C., Dimitriou, N., Brieu, N., Nearchou, I. P., Arandelovic, O., Schmidt, G., Harrison, D. J. & Caie, P. D., 1 Apr 2021, In: Cancers. 13, 7, 1624.

    Research output: Contribution to journalArticlepeer-review

  2. Automated detection and classification of desmoplastic reaction at the colorectal tumour front using deep learning

    Nearchou, I. P., Ueno, H., Kajiwara, Y., Lillard, K., Mochizuki, S., Takeuchi, K., Harrison, D. J. & Caie, P. D., 31 Mar 2021, In: Cancers. 13, 7, 1615.

    Research output: Contribution to journalArticlepeer-review

  3. Recommendations for cellular and molecular pathology input into clinical trials: a systematic review and meta-aggregation

    Lim, S. J., Gurusamy, K., O'Connor, D., Shaaban, A. M., Brierley, D., Lewis, I., Harrison, D., Kendall, T. J. & Robinson, M., 26 Feb 2021, In: The Journal of Pathology: Clinical Research. Early View, 12 p.

    Research output: Contribution to journalReview articlepeer-review

  4. Tissue-specific immunopathology in fatal COVID-19

    ICECAP consortium, Dorward, D. A., Russell, C. D., Um, I. H., Elshani, M., Armstrong, S. D., Penrice-Randal, R., Millar, T., Lerpiniere, C. E. B., Tagliavini, G., Hartley, C. S., Randle, N. P., Gachanja, N. N., Potey, P. M. D., Dong, X., Anderson, A. M., Campbell, V. L., Duguid, A. J., Al Qsous, W., BouHaidar, R. & 9 others, Baillie, J. K., Dhaliwal, K., Wallace, W. A., Bellamy, C. O. C., Prost, S., Smith, C., Hiscox, J. A., Harrison, D. J. & Lucas, C. D., 15 Jan 2021, In: American Journal of Respiratory and Critical Care Medicine. 203, 2, p. 192-201

    Research output: Contribution to journalArticlepeer-review

Related by journal

  1. CamGFR v2: a new model for estimating the glomerular filtration rate from standardized or non-standardized creatinine in patients with cancer

    Williams, E. H., Flint, T. R., Connell, C. M., Giglio, D., Lee, H., Ha, T., Gablenz, E., Bird, N. J., Weaver, J. M. J., Potts, H., Whitley, C. T., Bookman, M. A., Lynch, A. G., Meyer, H. V., Tavaré, S. & Janowitz, T., 12 Jan 2021, In: Clinical Cancer Research. Online First

    Research output: Contribution to journalArticlepeer-review

  2. Lucitanib for the treatment of HR+/HER2- metastatic breast cancer: results from the multicohort phase II FINESSE study

    Hui, R., Pearson, A., Cortes, J., Campbell, C., Poirot, C., Azim, H. A., Fumagalli, D., Lambertini, M., Daly, F., Arahmani, A., Perez-Garcia, J., Aftimos, P., Bedard, P. L., Xuereb, L., Scheepers, E. D., Vicente, M., Goulioti, T., Loibl, S., Loi, S., Pierrat, M-J. & 3 others, Turner, N. C., Andre, F. & Curigliano, G., 15 Jan 2020, In: Clinical Cancer Research. 26, 2, p. 354-363 10 p.

    Research output: Contribution to journalArticlepeer-review

  3. Sunitinib treatment exacerbates intratumoral heterogeneity in metastatic renal cancer

    Stewart, G. D., O'Mahony, F., Laird, A., Eory, L., Lubbock, A., Mackay, A., Nanda, J., O'Donnell, M., Mullen, P., McNeill, A., Riddick, A., Berney, D., Bex, A., Aitchison, M., Overton, I. M., Harrison, D. J. & Powles, T., Sep 2015, In: Clinical Cancer Research. 21, 18, p. 4212-4223

    Research output: Contribution to journalArticlepeer-review

  4. The effect of VEGF targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer

    Sharpe, K., Stewart, G. D., Mackay, A., Van Neste, C., Rofe, C., Berney, D. M., Kayani, I., Bex, A., Wan, E., O'Mahony, F., O'Donnell, M., Chowdhury, S., Doshi, R., Ho Yen, C., Gerlinger, M., Baker, D., Smith, N. R., Davies, B. R., Sahdev, A., Boleti, E. & 7 others, de Meyer, T., Van Criekinge, W., Beltran, L., Lu, Y-J., Harrison, D., Reynolds, A. R. & Powles, T., 15 Dec 2013, In: Clinical Cancer Research. 19, 24, p. 6294-6934 641 p.

    Research output: Contribution to journalArticlepeer-review

ID: 273354114